Youre likely to experience blurry vision, and you might have a cyst on your eyelid, along with visibly broken blood vessels
Approved in November 2023, Zepbound is a dual agonist targeting both GLP-1 and GIP receptors
Highrisk individuals without diagnosed diabetes Some people sit in the danger zone without yet meeting criteria for diabetes or overt cardiovascular disease. Common red flags: MASLD or fatty liver on ultrasound or MRI Strong family history of early heart attack or stroke Borderlinehigh blood pressure and/or lipids A steadily expanding waistline despite normal fasting glucose Because this pattern often precedes diabetes and heart disease, carefully targeted intervention potentially including tirzepatide inside a broader plan may help bend their risk curve before diagnoses pile up. 4
Whilst Rybelsus pharmacologically slows gastric emptying as part of its therapeutic action, a causal relationship with true gastroparesis has not been established
During a PlushCare visit, your clinician is not just checking BMI criteria for semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound)
However, anecdotal reports and the complex interplay between metabolic changes, weight loss, and underlying diabetes warrant careful consideration